Libtayo® (cemiplimab) approved in japan for advanced or recurrent cervical cancer

Tarrytown, n.y. , dec. 23, 2022 /prnewswire/ -- regeneron pharmaceuticals (nasdaq: regn) today announced that the ministry of health, labor and welfare (mhlw) in japan has granted marketing and manufacturing authorization for libtayo® (cemiplimab) as monotherapy to treat patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy.
REGN Ratings Summary
REGN Quant Ranking